Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals

Astrid J Hjelholt; Evelina Charidemou; Julian L Griffin; Steen B Pedersen; Anders Gudiksen; Henriette Pilegaard; Niels Jessen; Niels Møller; Jens O L Jørgensen

doi:10.1007/s00125-020-05262-w

Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals

Astrid J Hjelholt^* (Corresponding Author), Evelina Charidemou, Julian L Griffin, Steen B Pedersen, Anders Gudiksen, Henriette Pilegaard, Niels Jessen, Niels Møller, Jens O L Jørgensen

^*Corresponding author for this work

The Rowett Institute of Nutrition and Health

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

AIMS/HYPOTHESIS: Growth hormone (GH) causes insulin resistance that is linked to lipolysis, but the underlying mechanisms are unclear. We investigated if GH-induced insulin resistance in skeletal muscle involves accumulation of diacylglycerol (DAG) and ceramide as well as impaired insulin signalling, or substrate competition between fatty acids and glucose.

METHODS: Nine GH-deficient male participants were randomised and examined in a 2 × 2 factorial design with and without administration of GH and acipimox (an anti-lipolytic compound). As-treated analyses were performed, wherefore data from three visits from two patients were excluded due to incorrect GH administration. The primary outcome was insulin sensitivity, expressed as the AUC of the glucose infusion rate (GIRAUC), and furthermore, the levels of DAGs and ceramides, insulin signalling and the activity of the active form of pyruvate dehydrogenase (PDHa) were assessed in skeletal muscle biopsies obtained in the basal state and during a hyperinsulinaemic-euglycaemic clamp (HEC).

RESULTS: Co-administration of acipimox completely suppressed the GH-induced elevation in serum levels of NEFA (GH versus GH+acipimox, p < 0.0001) and abrogated GH-induced insulin resistance (mean GIRAUC [95% CI] [mg min-1 kg-1] during the HEC: control, 595 [493, 718]; GH, 468 [382, 573]; GH+acipimox, 654 [539, 794]; acipimox, 754 [618, 921]; GH vs GH+acipimox: p = 0.004). GH did not significantly change either the accumulation of DAGs and ceramides or insulin signalling in skeletal muscle, but GH antagonised the insulin-stimulated increase in PDHa activity (mean ± SEM [% from the basal state to the HEC]: control, 47 ± 19; GH, -15 ± 21; GH+acipimox, 3 ± 21; acipimox, 57 ± 22; main effect: p = 0.02).

CONCLUSIONS/INTERPRETATION: GH-induced insulin resistance in skeletal muscle is: (1) causally linked to lipolysis; (2) not associated with either accumulation of DAGs and ceramides or impaired insulin signalling; (3) likely to involve substrate competition between glucose and lipid intermediates.

Original language	English
Pages (from-to)	2641-2653
Number of pages	13
Journal	Diabetologia
Volume	63
Issue number	12
Early online date	18 Sept 2020
DOIs	https://doi.org/10.1007/s00125-020-05262-w
Publication status	Published - 1 Dec 2020

Bibliographical note

Acknowledgements:
We are grateful for the excellent technical assistance provided by A. Mengel, H. Petersen, L. Pedersen and H. Zibrandtsen, Aarhus University Hospital. We also owe great thanks to the participants for their commitment to this study.
Funding:
The work was supported by the Grant for Growth Innovation (GGI), which was funded by Merck KGaA, Darmstadt, Germany. The study funder was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.
JOLJ has received unrestricted research grants and lecture fees from Pfizer. JLG and EC were funded by the UK Medical Research Council (MC_UP_A090_1006, MC_PC_13030, MR/P011705/1 and MR/P01836X/1).

Keywords

Pyruvate dehydrogenase activity
Insulin resistance
Insulin signalling
Growth hormone
Ceramides
Fatty acids
Diacylglycerols
Acipimox

Access to Document

10.1007/s00125-020-05262-wLicence: Unspecified

Fingerprint

Dive into the research topics of 'Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals'. Together they form a unique fingerprint.

Cite this

Hjelholt, A. J., Charidemou, E., Griffin, J. L., Pedersen, S. B., Gudiksen, A., Pilegaard, H., Jessen, N., Møller, N., & Jørgensen, J. O. L. (2020). Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals. Diabetologia, 63(12), 2641-2653. https://doi.org/10.1007/s00125-020-05262-w

Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals. / Hjelholt, Astrid J (Corresponding Author); Charidemou, Evelina; Griffin, Julian L et al.
In: Diabetologia, Vol. 63, No. 12, 01.12.2020, p. 2641-2653.

Research output: Contribution to journal › Article › peer-review

Hjelholt, AJ, Charidemou, E, Griffin, JL, Pedersen, SB, Gudiksen, A, Pilegaard, H, Jessen, N, Møller, N & Jørgensen, JOL 2020, 'Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals', Diabetologia, vol. 63, no. 12, pp. 2641-2653. https://doi.org/10.1007/s00125-020-05262-w

Hjelholt AJ, Charidemou E, Griffin JL, Pedersen SB, Gudiksen A, Pilegaard H et al. Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals. Diabetologia. 2020 Dec 1;63(12):2641-2653. Epub 2020 Sept 18. doi: 10.1007/s00125-020-05262-w

@article{ce8a83d629744a33a872078e74f4896d,

title = "Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals",

abstract = "AIMS/HYPOTHESIS: Growth hormone (GH) causes insulin resistance that is linked to lipolysis, but the underlying mechanisms are unclear. We investigated if GH-induced insulin resistance in skeletal muscle involves accumulation of diacylglycerol (DAG) and ceramide as well as impaired insulin signalling, or substrate competition between fatty acids and glucose.METHODS: Nine GH-deficient male participants were randomised and examined in a 2 × 2 factorial design with and without administration of GH and acipimox (an anti-lipolytic compound). As-treated analyses were performed, wherefore data from three visits from two patients were excluded due to incorrect GH administration. The primary outcome was insulin sensitivity, expressed as the AUC of the glucose infusion rate (GIRAUC), and furthermore, the levels of DAGs and ceramides, insulin signalling and the activity of the active form of pyruvate dehydrogenase (PDHa) were assessed in skeletal muscle biopsies obtained in the basal state and during a hyperinsulinaemic-euglycaemic clamp (HEC).RESULTS: Co-administration of acipimox completely suppressed the GH-induced elevation in serum levels of NEFA (GH versus GH+acipimox, p < 0.0001) and abrogated GH-induced insulin resistance (mean GIRAUC [95% CI] [mg min-1 kg-1] during the HEC: control, 595 [493, 718]; GH, 468 [382, 573]; GH+acipimox, 654 [539, 794]; acipimox, 754 [618, 921]; GH vs GH+acipimox: p = 0.004). GH did not significantly change either the accumulation of DAGs and ceramides or insulin signalling in skeletal muscle, but GH antagonised the insulin-stimulated increase in PDHa activity (mean ± SEM [% from the basal state to the HEC]: control, 47 ± 19; GH, -15 ± 21; GH+acipimox, 3 ± 21; acipimox, 57 ± 22; main effect: p = 0.02).CONCLUSIONS/INTERPRETATION: GH-induced insulin resistance in skeletal muscle is: (1) causally linked to lipolysis; (2) not associated with either accumulation of DAGs and ceramides or impaired insulin signalling; (3) likely to involve substrate competition between glucose and lipid intermediates.",

keywords = "Pyruvate dehydrogenase activity, Insulin resistance, Insulin signalling, Growth hormone, Ceramides, Fatty acids, Diacylglycerols, Acipimox",

author = "Hjelholt, {Astrid J} and Evelina Charidemou and Griffin, {Julian L} and Pedersen, {Steen B} and Anders Gudiksen and Henriette Pilegaard and Niels Jessen and Niels M{\o}ller and J{\o}rgensen, {Jens O L}",

note = "Acknowledgements: We are grateful for the excellent technical assistance provided by A. Mengel, H. Petersen, L. Pedersen and H. Zibrandtsen, Aarhus University Hospital. We also owe great thanks to the participants for their commitment to this study. Funding: The work was supported by the Grant for Growth Innovation (GGI), which was funded by Merck KGaA, Darmstadt, Germany. The study funder was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report. JOLJ has received unrestricted research grants and lecture fees from Pfizer. JLG and EC were funded by the UK Medical Research Council (MC_UP_A090_1006, MC_PC_13030, MR/P011705/1 and MR/P01836X/1).",

year = "2020",

month = dec,

day = "1",

doi = "10.1007/s00125-020-05262-w",

language = "English",

volume = "63",

pages = "2641--2653",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer ",

number = "12",

}

TY - JOUR

T1 - Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle

T2 - a 2 × 2 factorial, randomised, crossover study in human individuals

AU - Hjelholt, Astrid J

AU - Charidemou, Evelina

AU - Griffin, Julian L

AU - Pedersen, Steen B

AU - Gudiksen, Anders

AU - Pilegaard, Henriette

AU - Jessen, Niels

AU - Møller, Niels

AU - Jørgensen, Jens O L

N1 - Acknowledgements: We are grateful for the excellent technical assistance provided by A. Mengel, H. Petersen, L. Pedersen and H. Zibrandtsen, Aarhus University Hospital. We also owe great thanks to the participants for their commitment to this study. Funding: The work was supported by the Grant for Growth Innovation (GGI), which was funded by Merck KGaA, Darmstadt, Germany. The study funder was not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report. JOLJ has received unrestricted research grants and lecture fees from Pfizer. JLG and EC were funded by the UK Medical Research Council (MC_UP_A090_1006, MC_PC_13030, MR/P011705/1 and MR/P01836X/1).

PY - 2020/12/1

Y1 - 2020/12/1

N2 - AIMS/HYPOTHESIS: Growth hormone (GH) causes insulin resistance that is linked to lipolysis, but the underlying mechanisms are unclear. We investigated if GH-induced insulin resistance in skeletal muscle involves accumulation of diacylglycerol (DAG) and ceramide as well as impaired insulin signalling, or substrate competition between fatty acids and glucose.METHODS: Nine GH-deficient male participants were randomised and examined in a 2 × 2 factorial design with and without administration of GH and acipimox (an anti-lipolytic compound). As-treated analyses were performed, wherefore data from three visits from two patients were excluded due to incorrect GH administration. The primary outcome was insulin sensitivity, expressed as the AUC of the glucose infusion rate (GIRAUC), and furthermore, the levels of DAGs and ceramides, insulin signalling and the activity of the active form of pyruvate dehydrogenase (PDHa) were assessed in skeletal muscle biopsies obtained in the basal state and during a hyperinsulinaemic-euglycaemic clamp (HEC).RESULTS: Co-administration of acipimox completely suppressed the GH-induced elevation in serum levels of NEFA (GH versus GH+acipimox, p < 0.0001) and abrogated GH-induced insulin resistance (mean GIRAUC [95% CI] [mg min-1 kg-1] during the HEC: control, 595 [493, 718]; GH, 468 [382, 573]; GH+acipimox, 654 [539, 794]; acipimox, 754 [618, 921]; GH vs GH+acipimox: p = 0.004). GH did not significantly change either the accumulation of DAGs and ceramides or insulin signalling in skeletal muscle, but GH antagonised the insulin-stimulated increase in PDHa activity (mean ± SEM [% from the basal state to the HEC]: control, 47 ± 19; GH, -15 ± 21; GH+acipimox, 3 ± 21; acipimox, 57 ± 22; main effect: p = 0.02).CONCLUSIONS/INTERPRETATION: GH-induced insulin resistance in skeletal muscle is: (1) causally linked to lipolysis; (2) not associated with either accumulation of DAGs and ceramides or impaired insulin signalling; (3) likely to involve substrate competition between glucose and lipid intermediates.

AB - AIMS/HYPOTHESIS: Growth hormone (GH) causes insulin resistance that is linked to lipolysis, but the underlying mechanisms are unclear. We investigated if GH-induced insulin resistance in skeletal muscle involves accumulation of diacylglycerol (DAG) and ceramide as well as impaired insulin signalling, or substrate competition between fatty acids and glucose.METHODS: Nine GH-deficient male participants were randomised and examined in a 2 × 2 factorial design with and without administration of GH and acipimox (an anti-lipolytic compound). As-treated analyses were performed, wherefore data from three visits from two patients were excluded due to incorrect GH administration. The primary outcome was insulin sensitivity, expressed as the AUC of the glucose infusion rate (GIRAUC), and furthermore, the levels of DAGs and ceramides, insulin signalling and the activity of the active form of pyruvate dehydrogenase (PDHa) were assessed in skeletal muscle biopsies obtained in the basal state and during a hyperinsulinaemic-euglycaemic clamp (HEC).RESULTS: Co-administration of acipimox completely suppressed the GH-induced elevation in serum levels of NEFA (GH versus GH+acipimox, p < 0.0001) and abrogated GH-induced insulin resistance (mean GIRAUC [95% CI] [mg min-1 kg-1] during the HEC: control, 595 [493, 718]; GH, 468 [382, 573]; GH+acipimox, 654 [539, 794]; acipimox, 754 [618, 921]; GH vs GH+acipimox: p = 0.004). GH did not significantly change either the accumulation of DAGs and ceramides or insulin signalling in skeletal muscle, but GH antagonised the insulin-stimulated increase in PDHa activity (mean ± SEM [% from the basal state to the HEC]: control, 47 ± 19; GH, -15 ± 21; GH+acipimox, 3 ± 21; acipimox, 57 ± 22; main effect: p = 0.02).CONCLUSIONS/INTERPRETATION: GH-induced insulin resistance in skeletal muscle is: (1) causally linked to lipolysis; (2) not associated with either accumulation of DAGs and ceramides or impaired insulin signalling; (3) likely to involve substrate competition between glucose and lipid intermediates.

KW - Pyruvate dehydrogenase activity

KW - Insulin resistance

KW - Insulin signalling

KW - Growth hormone

KW - Ceramides

KW - Fatty acids

KW - Diacylglycerols

KW - Acipimox

U2 - 10.1007/s00125-020-05262-w

DO - 10.1007/s00125-020-05262-w

M3 - Article

C2 - 32945898

SN - 0012-186X

VL - 63

SP - 2641

EP - 2653

JO - Diabetologia

JF - Diabetologia

IS - 12

ER -